# Dapagliflozin in the Prevention of Post-Coronary Angioplasty Acute Kidney Injury

> **NCT05435235** · PHASE4 · SUSPENDED · sponsor: **Albert Einstein Healthcare Network** · enrollment: 250 (estimated)

## Conditions studied

- Acute Kidney Injury
- Percutaneous Coronary Intervention

## Interventions

- **DRUG:** Dapagliflozin 10mg Tab

## Key facts

- **NCT ID:** NCT05435235
- **Lead sponsor:** Albert Einstein Healthcare Network
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2024-09-01
- **Primary completion:** 2025-06
- **Final completion:** 2025-06
- **Target enrollment:** 250 (ESTIMATED)
- **Why stopped:** Laboratory UNGAL
- **Last updated:** 2024-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05435235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05435235, "Dapagliflozin in the Prevention of Post-Coronary Angioplasty Acute Kidney Injury". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05435235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*